Related Experiment Video
Updated: Sep 24, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer
Sitapriya Moorthi1, Alice H Berger1,2,3
1Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Abstract:
Lung cancers in never- and light-smokers often harbor targetable oncogenic mutations in Ras pathway genes. Here, a novel OCLN-RASGRF1 fusion is identified in an otherwise Ras wild-type lung tumor. Studying this and other RASGRF1 fusions, the authors show that these fusions lead to malignant phenotypes that can be reversed by MEK inhibition. See related article by Hunihan et al., p. 3091.
Insights
A new OCLN-RASGRF1 fusion drives lung cancer in some patients. Researchers found these fusions cause malignant growth that MEK inhibitors can reverse, offering potential new lung cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancers in never-smokers and light-smokers frequently exhibit targetable oncogenic mutations within Ras pathway genes.
- The Ras signaling pathway is a critical regulator of cell proliferation, differentiation, and survival, and its dysregulation is implicated in numerous cancers.
More Related Videos
Related Concept Videos
Abnormal Proliferation
The Ras Gene
Ras is a...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

